Kamada (NASDAQ:KMDA) Now Covered by Analysts at Benchmark

Stock analysts at Benchmark started coverage on shares of Kamada (NASDAQ:KMDA) in a research note issued on Friday, MarketBeat reports. The firm set a “buy” rating and a $15.00 price target on the biotechnology company’s stock. Benchmark’s target price would indicate a potential upside of 125.56% from the stock’s current price.

Other research analysts have also recently issued reports about the stock. StockNews.com raised shares of Kamada from a “buy” rating to a “strong-buy” rating in a report on Thursday, March 13th. HC Wainwright reissued a “buy” rating and set a $11.00 price target on shares of Kamada in a report on Thursday, March 6th.

Kamada Stock Performance

NASDAQ KMDA opened at $6.65 on Friday. Kamada has a one year low of $4.74 and a one year high of $9.16. The stock has a 50-day moving average of $7.21 and a 200 day moving average of $6.24. The company has a market capitalization of $382.24 million, a price-to-earnings ratio of 23.75, a PEG ratio of 0.97 and a beta of 0.97.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. NewEdge Advisors LLC grew its position in shares of Kamada by 54.2% during the fourth quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company’s stock worth $143,000 after purchasing an additional 8,260 shares in the last quarter. Aristides Capital LLC boosted its stake in Kamada by 12.1% in the 4th quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company’s stock worth $387,000 after purchasing an additional 6,850 shares during the period. Geode Capital Management LLC grew its holdings in Kamada by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company’s stock valued at $178,000 after buying an additional 1,549 shares in the last quarter. JPMorgan Chase & Co. bought a new stake in shares of Kamada during the fourth quarter valued at approximately $67,000. Finally, Public Employees Retirement System of Ohio purchased a new position in shares of Kamada in the third quarter worth $77,000. Institutional investors own 20.38% of the company’s stock.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.